Isolation and Characterization of R-Enantiomer in Ezetimibe


A simple and rapid Supercritical Fluid Chromatography (SFC) method has been developed to isolate and characterize R-Isomer of Ezetimi be by using normal phase Chiral Cel OD-H with 250 mm × 30 mm, 5 microns column using a mobile phase system containing super critical fluid carbondi oxide (Co2) and the percentage of 2-Propanol as a mobile phase (85:15) and detection at 230 nm. The isolated R-Isomer is characterized by using UV-vis, FT-IR, ESI-MS, HPLC1H and 13C NMR. The purity of isolated R-Isomer is about 98%.

Share and Cite:

K. Chimalakonda, V. Kamani, M. Gutta, S. Polisetty and S. Srinivas Koduri, "Isolation and Characterization of R-Enantiomer in Ezetimibe," American Journal of Analytical Chemistry, Vol. 4 No. 9, 2013, pp. 488-495. doi: 10.4236/ajac.2013.49062.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] H. Caner, E. Groner, L. Levy and I. Agranat, “Trends in the Development of Chiral Drugs,” Drug Discovery Today, Vol. 9, No. 3, 2004, pp. 105-110. doi:10.1016/S1359-6446(03)02904-0
[2] J. Caldwell, “Importance of Stereospecific Bionalytical Monitoring in Drug Development,” Journal of Chromatography A, Vol. 719, No. 1, 1996, pp. 3-13. doi:10.1016/0021-9673(95)00465-3
[3] N. M. Maier, P. Franco and W. Lindner, “Separation of Enantiomers: Needs Challenges, Perspectives,” Journal of Chromatography A, Vol. 906, No. 3, 2001, pp. 3-33. doi:10.1016/S0021-9673(00)00532-X
[4] T. E. Beesley and R. P. W. Scott, “Chiral Chromatography,” John Wiley & Sons, Ltd., New York, 1998, pp. 23-26.
[5] E. Leitersdorf, “Selective Cholesterol Absorption Inhibition: A Novel Strategy in Lipid-Lowering Management,” International Journal of Clinical Practice, Vol. 56, No. 2, 2002, pp. 116-119.
[6] M. Von Heek, C. Farley and D. S. Compton, “Ezetimibe Selectively Inhibits Intestinal Cholesterol Absorption in Rodents in Presence and Absence of Exocrine Pancreatic Function,” British Journal of Pharmacology, Vol. 134, No. 2, 2001, pp. 409-417.
[7] S. Singh, B. Singh, R. Bahuguna, L. Wadhwa and R. Saxena, “Stress Degradation Studies on Ezetimibe and Development of a Validated Stability-Indicating HPLC Assay,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 41, No. 3, 2006, pp. 1037-1040. doi:10.1016/j.jpba.2006.01.030
[8] R. Sistla, V. S. Tata, Y. V. Kashyap, D. Chandrasekar and P. V. Diwan, “Development and Validation of a Reversed-Phase HPLC Method for the Determination of Ezetimibe in Pharmaceutical Dosage Forms,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, No. 3-4, 2005, pp. 517-522. doi:10.1016/j.jpba.2005.04.026
[9] T. L. Chester, “The Role of Supercritical Fluid Chromatography in Analytical Chemistry,” Journal of Chromatographic Science, Vol. 24, No. 6, 1986, pp. 226-229. doi:10.1093/chromsci/24.6.226

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.